|
Creating a research and development ecosystem that will deliver the next generation of treatments means having the right incentive framework as well as addressing the scientific and regulatory challenges in the development of new treatments for rare diseases. (...)
We have witnessed the power of incentives in stimulating research. Since the EU Orphan Regulation was adopted in 2000, clinical trials in rare diseases have increased by 88% and 230 SMEs have been launched focusing on rare disease research. Understanding how breakthroughs in rare disease occur is key to creating incentives that really work in the new regulation.
|
